(Leander) L.R. Buisman PhD

All publications (22)

• Article (16)

  • A. Wagstaff, G. Flores, J. Hsu, M. Smitz, K. Chepynoga, L.R. Buisman, K.J. van Wilgenburg & P. Eozenou (2018). Progress on catastrophic health spending in 133 countries: a retrospective observational study. The Lancet Global Health, 6 (2), e169-e179. doi: 10.1016/S2214-109X(17)30429-1
  • A. Wagstaff, G. Flores, J. Hsu, M. Smitz, K. Chepynoga, L.R. Buisman, K. Van Wilgenburg & P. Eozenou (2018). Progress on catastrophic health spending in 133 countries: a retrospective observational study. The Lancet Global Health, 6 (2), e169-e179. doi: 10.1016/S2214-109X(17)30429-1 [go to publisher's site]
  • T.M. Kuijper, L.R. Buisman, J.M. Hazes & A.E.A.M. Weel (2017). Cost-effectiveness of Biological Disease-modifying Antirheumatic Drugs for the Treatment of Rheumatoid Arthritis: Implications for Clinical Practice. Journal of Rheumatology, 44 (7), 965-967. doi: 10.3899/jrheum.170334 [go to publisher's site]
  • C. Bredenkamp & L.R. Buisman (2017). Twenty Years of Progress on Maternal and Child Health in the Philippines: An Equity Lens. Asia Pacific Journal of Public Health, 29 (5), 367-376. doi: 10.1177/1010539517715367
  • P. de Jong, J.M.W. Hazes, L.R. Buisman, P. Barendregt, D. van Zeben, P. van der Lubbe, A. Gerards, M. de Jager, P. de Sonnaville, B. Grillet, J.J. Luime & A.E.A.M. Weel (2016). Best cost-effectiveness and worker productivity with initial triple DMARD therapy compared with methotrexate monotherapy in early rheumatoid arthritis: cost-utility analysis of the tREACH trial. Rheumatology, 55 (12), 2138-2147.
  • L.R. Buisman, J.J. Luime, M. Oppe, J.M.W. Hazes & M.P.M.H. Rutten - van Molken (2016). A five-year model to assess the early cost-effectiveness of new diagnostic tests in the early diagnosis of rheumatoid arthritis. Arthritis Research & Therapy, 18 (1):135. doi: 10.1186/s13075-016-1020-3
  • A. Wagstaff, D. Cotlear, P. Hoang-Vu Eozenou & L.R. Buisman (2016). Measuring progress towards universal health coverage: with an application to 24 developing countries. Oxford Review of Economic Policy, 32 (1), 147-189. doi: 10.1093/oxrep/grv019
  • L.R. Buisman, M.P.M.H. Rutten - van Molken, D. Postmus, J.J. Luime, C.A. de Uyl-de Groot & W.K. Redekop (2016). The early bird catches the worm: early cost-effectiveness analysis of new medical tests. International Journal of Technology Assessment in Health Care, 32 (1-2), 46-53. doi: 10.1017/S0266462316000064
  • L.R. Buisman, A.J. Rijnsburger, H. den Hertog, A. van der Lugt & W.K. Redekop (2016). Clinical Practice Variation Needs to be Considered in Cost-Effectiveness Analyses: A Case Study of Patients with a Recent Transient Ischemic Attack or Minor Ischemic Stroke. Applied Health Economics and Health Policy, 14 (1), 67-75. doi: 10.1007/s40258-015-0167-4
  • C. Bredenkamp & L.R. Buisman (2016). Financial protection from health spending in the Philippines: policies and progress. Health Policy and Planning, 31 (7), 919-927. doi: 10.1093/heapol/czw011
  • J.J. Luime, L.R. Buisman, M. Oppe, J.M.W. Hazes & M.P.M.H. Rutten - van Molken (2016). Cost-effectiveness model for evaluating new diagnostic tests in the work-up of patients with inflammatory arthritis at risk of having Rheumatoid Arthritis. Arthritis Care & Research, 68 (7), 927-935. doi: 10.1002/acr.22776
  • A. Wagstaff, T. Dmytraczenko, G. Almeida, L.R. Buisman, P. Hoang-Vu Eozenou, C. Bredenkamp, J.A. Cercone, Y. Diaz, D. Maceira, S. Molina, G. Paraje, F. Ruiz, F. Sarti, J. Scott, M. Valdivia & H. Werneck (2015). Assessing Latin America's Progress Toward Achieving Universal Health Coverage. Health Affairs, 34 (10), 1704-1712. doi: 10.1377/hlthaff.2014.1453
  • L.R. Buisman, S.S. Tan, P.J. Nederkoorn, P.J. Koudstaal & W.K. Redekop (2015). Hospital costs of ischemic stroke and TIA in the Netherlands. Neurology, 84 (22), 2208-2215. doi: 10.1212/WNL.0000000000001635
  • L.R. Buisman & P. Garcia Gomez (2015). Inequity in inpatient healthcare utilisation 10 years after Apartheid. Development Southern Africa, 32 (2), 193-208. doi: 10.1080/0376835X.2014.984374
  • A. Wagstaff, C. Bredenkamp & L.R. Buisman (2014). Progress on Global Health Goals: are the Poor Being Left Behind? World Bank Research Observer, 29 (2), 137-162. doi: 10.1093/wbro/lku008
  • C. Bredenkamp, L.R. Buisman & E. van de Poel (2014). Persistent inequalities in child undernutrition: Evidence from 80 countries from 1990 to today. International Journal of Epidemiology, 43 (4), 1328-1335. doi: 10.1093/ije/dyu075

• Report (5)

  • A. Somanathan, I. Sheiman, S. Salakhutdinova & L.R. Buisman (2018). Universal Health Coverage in Russia: Extending Coverage for the Poor in the Post-Soviet Era. (Preprints, UNIVERSAL HEALTH COVERAGE STUDY SERIES, no 37). Washington, DC: World Bank Group
  • C. Bredenkamp & L.R. Buisman (2015). Universal Health Coverage in the Philippines: Progress on Financial Protection Goals. (Preprints, Policy Research Working Paper, no 7258). : World Bank
  • A. Wagstaff, D. Cotlear, P. Hoang-Vu Eozenou & L.R. Buisman (2015). Measuring Progress towards Universal Health Coverage : With an Application to 24 Developing Countries. (Preprints, Policy Research Working Paper, no 7470). : World Bank
  • A. Wagstaff, C. Bredenkamp & L.R. Buisman (2014). Progress Toward the Health MDGs Are the Poor Being Left Behind? (Preprints, Policy Research Working Paper, no 6894). : World Bank
  • A. Wagstaff, M. Bilger, L.R. Buisman & C. Bredenkamp (2014). Who Benefits from Government Health Spending and Why? A Global Assessment. (Preprints, Policy Research Working Paper, no 7044). : World Bank

• Doctoral thesis (1)

  • L.R. Buisman (2016, juni 30). Early cost-effectiveness of medical tests in rheumatoid arthritis and ischemic stroke. EUR Prom./coprom.: prof.dr. M.P.M.H. Rutten - van Molken & dr. W.K. Redekop.

Present position